ClinicalTrials.gg
Status unknownNCT05044091HOPEIUpdated Sep 14, 2021

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

An observational study in Ovarian Cancer, HRD and PARP Inhibitor, sponsored by Xiaoxiang Chen. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Xiaoxiang Chen · Observational

How we know · 4 judgments

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Ovarian Neoplasms with a site in China — 201 open to participants now, 233 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
51st of 73
100 · median 200
Started
2021
with 43 others
Observational
73 of 395
36 open now
Registered
135th of 395
by date

Among the 395 studies in Ovarian Neoplasms with a site in China, this one is the 51st largest by planned enrollment of the 73 observational ones that give a count, is one of 44 that started in 2021, is one of 73 observational ones, and was the 135th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

201 of the 395 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

196 more — sign in →

All 201 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

Read the detailed description

This study intends to perform HRD testing of ovarian cancer in real world from China and correlate HRD status and clinical characteristics with therapeutic outcomes.

03

Conditions studied

  • Ovarian Cancer
  • HRD
  • PARP Inhibitor

Browse trials for

Keywords

  • Ovarian caner, HRD, PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Ovarian/fallopian tube/primary peritoneal cancer patients treated with PARP inhibitor in the real word.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects join the study voluntarily and sign ;
  2. Female subjects are older than 18 years;
  3. (Eastern Cooperative Oncology Group) physical status score is 0-2;
  4. ≥3 months;
  5. confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous or endometrioid histology;
  6. Patients received PARP inhibitor as maintenance therapy or monotherapy for more than four weeks.

Exclusion criteria

Exclusion Criteria:

  1. Personnel involved in the formulation or implementation of the research plan;
  2. Patient participated in other clinical trails using other experimental drugs at the same time as the study;
  3. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ;
  4. Previous or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);
  5. Patients who are pregnant or lactation, or who plan to become pregnant during study treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • ovarian/fallopian tube/primary peritoneal cancer patients

    ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks

    Drug: PARP inhibitor

Interventions

  • DrugPARP inhibitorsStudies of PARP inhibitorsPARP inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions

    Also known as: Lynparza, Zejula

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by RECIST1.1.

    Time frame: Through study completion, an average of 1 year

  2. Progression Free Survival (PFS)

    PFS is defined as the time in months from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death as assessed by RECIST1.1.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • Xiaoxiang Chen, MD,PhD
    Nanjing, Jiangsu 210009, China
08

References and documents

Individual participant data

Plan to share: No — Contact Prof. Chen and Dr. Ni for primary data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2021; primary completion for Sep 2022, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2021
First posted
Sep 14, 2021
StartEst.
Sep 15, 2021
Primary completionEst.
Sep 2022
CompletionEst.
Sep 2023
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05044091
Lead sponsor
Xiaoxiang Chen
Responsible party
Xiaoxiang Chen (Academic secretary of gynecological oncology Committee of Jiangsu anti cancer association, Jiangsu Cancer Institute & Hospital) — Sponsor-investigator
First posted
Sep 14, 2021
Start date
Sep 15, 2021 (estimated)
Primary completion
Sep 2022 (estimated)
Completion
Sep 2023 (estimated)
Last update
Sep 14, 2021

Study contacts

Jing Ni, MD
Contact
nijingwulin@126.com
+86 13327833586
Xiaoxiang Chen, MD,PhD
Contact
Xiaoxiang Chen, MD,PhD
study chair · Jiangsu Cancer Institute & Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion